Viracta Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

• Viracta Therapeutics Inc VIRX.OQ reported a quarterly adjusted loss of 27 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -33 cents. The mean expectation of two analysts for the quarter was for a loss of 24 cents per share. Wall Street expected results to range from -28 cents to -21 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Viracta Therapeutics Inc's reported EPS for the quarter was a loss of 27 cents​.

• The company reported a quarterly loss of $10.55 million.

• Viracta Therapeutics Inc shares had fallen by 23.6% this quarter and lost 69.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is "hold."

Wall Street's median 12-month price target for Viracta Therapeutics Inc is 3.50

This summary was machine generated from LSEG data November 13 at 02:16 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)